FDA Panel Wants More Data for Astra's Olaparib

Safety concerns over the PARP inhibitor warranted the request for additional data.
Published Online: June 25, 2014

An advisory panel to the U.S. Food and Drug Administration recommended on Wednesday that AstraZeneca Plc be required to submit further clinical data before its experimental ovarian cancer drug is approved.

The panel voted 11-2 that the company should complete a second trial to confirm results seen in a smaller study which, while positive, were not robust enough to convince the committee that they could be reproduced. Panel members expressed concern about a potential increased risk of secondary cancers in patients receiving the drug, olaparib, as well as side effects such as nausea and gastrointestinal disturbances.

The FDA is not obliged to follow the advice of its advisory panels but typically does so. Olaparib is one of several cancer drugs AstraZeneca flagged as having strong potential in its defense of a $118 billion take-over bid by Pfizer Inc.

Original report: http://reut.rs/1mfMHCT

Source: Reuters

Recommended Articles
The announced price for alirocumab, the first PCSK9 inhibitor approved for use in the US, was the top story in managed care this week. Also, HHS announced $100 million available to combat substance abuse, and Medicare and Medicaid turn 50 years old.
A study published in JAMA Oncology presents a new tool that can predict disease recurrence in oropharyngeal cancer patients.
Proposed mergers of Aetna and Humana, and Anthem and Cigna, raise questions of whether consumers will continue to see competition in health insurance markets.
Urologists at Cancer Research UK have identified 5 distinct genomic signatures in prostate cancer that can have important implications on treatment decisions.
Fifty years ago today, President Lyndon B. Johnson signed the law that created Medicare and Medicaid, setting in motion not only the greatest change in healthcare in the nation's history at that point, but also a lasting change for society.